Tag: gene therapy for parkinson’s disease market size

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Gene Therapy For Parkinson’s Disease Market Set To Climb From $0.81 Billion In 2026 To $2.04 Billion By 2030

The market for gene therapy targeting Parkinson’s disease has experienced significant expansion in recent years. This market is projected to expand from $0.64 billion in 2025 to $0.81 billion in 2026, at a compound annual growth rate (CAGR) of 26.3%. The growth observed in the historic period can be attributed to several factors, including advancements in viral vector engineering, a deeper understanding of Parkinson’s disease pathology, increased funding for neuroscience research, the availability of enhanced delivery technologies, and promising outcomes from initial clinical trials.

The gene therapy sector for Parkinson’s disease is anticipated to undergo substantial expansion in the upcoming years. Its valuation is predicted to reach $2.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.0%. This projected growth can be attributed to several factors including increased funding for neurodegenerative disease treatments, the rising adoption of personalized gene therapy approaches, the expansion of late-stage clinical trial pipelines, an escalating demand for disease-modifying therapies, and advancements in minimally invasive delivery methods. Prominent trends for the forecast period encompass the increasing development of viral vector-based therapies, a growing focus on dopamine restoration strategies, the expanding application of neurotrophic factor gene delivery, the proliferation of precision intracerebral delivery techniques, and an elevated emphasis on long-term therapeutic efficacy.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=11194409&type=smp&name=Gene%20Therapy%20For%20Parkinson%E2%80%99s%20Disease%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Gene Therapy For Parkinson’s Disease Market Growth Factors: What’s Supporting Expansion?

The gene therapy for Parkinson’s disease market is anticipated to expand propelled by the increasing focus on personalized medicine. This medical strategy customizes treatment and prevention plans based on an individual’s genetic makeup, lifestyle, and environment. The rising demand for targeted therapies, which improve treatment effectiveness and minimize adverse side effects, is fueling the growing interest in personalized medicine. In this context, gene therapy for Parkinson’s disease delivers tailored genetic modifications to restore dopamine function and address unique patient-specific disease mechanisms. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, stated that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, representing a notable increase from the 6 approvals in 2022. Therefore, the surging interest in personalized medicine is a primary driver for the growth of the gene therapy for Parkinson’s disease market.

Gene Therapy For Parkinson’s Disease Market Segments: Where Is Growth Concentrated?

The gene therapy for parkinson’s disease market covered in this report is segmented –

1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy

2) By Vector Type: Viral Vectors, Non-Viral Vectors

3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes

4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods

5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors

2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy

Gene Therapy For Parkinson’s Disease Market Industry Trends: What’s Reshaping Demand?

Within the gene therapy for Parkinson’s disease market, major companies are actively developing more precise therapies, such as regenerative medicine advanced therapy, aiming to improve neuronal survival, restore dopamine function, and offer long-lasting disease-modifying advantages for patients. Regenerative medicine advanced therapy (RMAT) is a specific designation from the United States Food and Drug Administration (FDA), granted to regenerative medicine products like cell therapies, gene therapies, and tissue-engineered products, designed to treat, modify, reverse, or cure serious or life-threatening conditions. For example, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy company, introduced AB-1005, an investigational AAV2-GDNF gene therapy that received FDA regenerative medicine advanced therapy (RMAT) designation. This designation, intended to accelerate the development and review of promising therapies, was provided based on data submitted by AskBio, including clinical evidence from its Phase Ib open-label, uncontrolled trial, which demonstrated AB-1005’s potential to slow disease progression and enhance motor function in Parkinson’s patients.

Gene Therapy For Parkinson’s Disease Market Key Participants And Competitive Landscape

Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

View The Full Gene Therapy For Parkinson’s Disease Market Report:

https://thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Gene Therapy For Parkinson’s Disease Market Global Footprint: Which Region Leads The Industry?

North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Gene Therapy For Parkinson’s Disease Market Value Analysis: What Growth Is Expected Over The Forecast Period?

The gene therapy for Parkinson’s disease market has experienced rapid expansion in recent years, increasing from $0.64 billion in 2025 to $0.81 billion in 2026, reflecting a compound annual growth rate (CAGR) of 26.3. This historical growth has been driven by progress in viral vector engineering, a deeper comprehension of Parkinson’s disease pathology, heightened investment in neuroscience research, the development of more effective delivery technologies, and encouraging outcomes from early-stage clinical trials.

The market for gene therapy targeting Parkinson’s disease is projected to experience exponential expansion in the coming years. By 2030, its value is anticipated to reach $2.05 billion, reflecting a compound annual growth rate (CAGR) of 26.0%. This forecasted growth is driven by heightened investment in treatments for neurodegenerative disorders, a greater uptake of customized gene therapy strategies, an expansion of advanced clinical trials in later stages, a rising need for therapies that alter disease progression, and improvements in minimally invasive delivery techniques. Key developments likely to shape this period include the growing creation of therapies based on viral vectors, an increased emphasis on methods to restore dopamine, broader application of neurotrophic factor gene delivery, refinement of precise intracerebral administration techniques, and a stronger focus on achieving sustained therapeutic outcomes over the long term.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Gene Therapy For Parkinson’s Disease Market Growth Momentum: Which Factors Are Influencing Demand?

The rising focus on personalized medicine is anticipated to drive expansion in the gene therapy market for Parkinson’s disease in the coming years. Personalized medicine is a medical strategy that customizes treatments and preventive measures according to an individual’s genetic profile, lifestyle, and environmental factors. This approach is gaining momentum because of an increasing need for targeted therapies that boost treatment efficacy and reduce unwanted side effects. Within the context of Parkinson’s disease, gene therapy in personalized medicine involves applying specific genetic alterations to restore dopamine function and address unique disease mechanisms in each patient. As an example, in February 2024, the Personalized Medicine Coalition, a nonprofit organization based in the United States, noted that the US Food and Drug Administration (FDA) authorized 16 new personalized therapies for patients with rare diseases in 2023, a significant jump from just 6 approvals recorded in 2022. Consequently, the heightened interest in personalized medicine is fueling growth in the market for gene therapy targeting Parkinson’s disease.

Gene Therapy For Parkinson’s Disease Market Segment Landscape: Which Areas Lead Market Development?

The gene therapy for parkinson’s disease market covered in this report is segmented –

1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy

2) By Vector Type: Viral Vectors, Non-Viral Vectors

3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes

4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods

5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors

2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy

Gene Therapy For Parkinson’s Disease Market Trends Reshaping Industry Growth

Key players in the gene therapy market for Parkinson’s disease are actively working on refining therapeutic approaches, including regenerative medicine advanced therapy, aimed at improving neuronal survival, restoring dopamine function, and delivering sustained disease-modifying advantages for individuals affected by Parkinson’s. Regenerative medicine advanced therapy (RMAT) is a specific classification from the U.S. Food and Drug Administration (FDA) assigned to regenerative medicine products—such as cell therapies, gene therapies, and tissue-engineered solutions—designed to treat, alter, reverse, or cure severe or life-threatening conditions. As an example, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy firm headquartered in the United States, unveiled AB-1005, an investigational AAV2-GDNF gene therapy that has been awarded FDA regenerative medicine advanced therapy (RMAT) designation. This designation, aimed at accelerating the development and review of promising treatments, was granted based on information submitted by AskBio, which included clinical findings from its Phase Ib open-label, uncontrolled trial, showing AB-1005’s ability to potentially decelerate disease advancement and enhance motor function in Parkinson’s patients.

Gene Therapy For Parkinson’s Disease Market Industry Leaders And Market Competition

Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

Access The Complete Gene Therapy For Parkinson’s Disease Market Report:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Gene Therapy For Parkinson’s Disease Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Gene Therapy For Parkinson’s Disease Market By 2030 Based On Its 2026 Value?

The gene therapy for parkinson’s disease market has witnessed substantial growth in recent years. This market is projected to expand from $0.64 billion in 2025 to $0.81 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 26.3%. Historically, this growth can be attributed to progress in viral vector engineering, an enhanced understanding of Parkinson’s disease pathology, increased funding for neuroscience research, the introduction of improved delivery technologies, and positive early clinical trial outcomes.

The gene therapy for parkinson’s disease market is projected to experience significant expansion in the coming years. It is expected to reach a value of $2.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.0%. This projected growth throughout the forecast period is driven by factors such as increasing investments in neurodegenerative disease therapies, a rising adoption of personalized gene therapy approaches, the expansion of late-stage clinical pipelines, a growing demand for disease-modifying treatments, and the advancement of minimally invasive delivery techniques. Prominent trends for the forecast period encompass the increasing development of viral vector-based therapies, a heightened focus on dopamine restoration approaches, the expanding use of neurotrophic factor gene delivery, the broadening of precision intracerebral delivery methods, and an enhanced emphasis on long-term therapeutic efficacy.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp

Which Major Factors Are Contributing To The Development Of The Gene Therapy For Parkinson’s Disease Market?

The gene therapy for Parkinson’s disease market is anticipated to expand due to the increasing focus on personalized medicine. Personalized medicine refers to a medical approach that customizes treatment and prevention plans according to an individual’s unique genetic profile, lifestyle, and environment. Interest in personalized medicine is escalating because of the rising demand for targeted interventions that enhance treatment effectiveness while minimizing adverse side effects. In the context of gene therapy for Parkinson’s disease, personalized medicine is utilized to deliver specific genetic modifications designed to restore dopamine function and address individual patient-specific disease mechanisms. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, marking a significant increase from the 6 approvals granted in 2022. Thus, the growing interest in personalized medicine is driving the growth of the gene therapy for Parkinson’s disease market.

How Are Different Segment Groups Identified Within The Gene Therapy For Parkinson’s Disease Market?

The gene therapy for parkinson’s disease market covered in this report is segmented –

1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy

2) By Vector Type: Viral Vectors, Non-Viral Vectors

3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes

4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods

5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors

2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy

Which Trends Are Expected To Shape The Gene Therapy For Parkinson’s Disease Market?

Leading companies within the gene therapy for Parkinson’s disease market are concentrating on creating more precise therapies, like regenerative medicine advanced therapy, to boost neuronal survival, restore dopamine function, and deliver lasting disease-modifying advantages for those with Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) signifies a specific United States Food and Drug Administration (FDA) designation awarded to regenerative medicine products, such as cell therapies, gene therapies, and tissue-engineered products, which aim to treat, modify, reverse, or cure serious or life-threatening illnesses. For instance, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy company, introduced AB-1005, an investigational AAV2-GDNF gene therapy that acquired FDA regenerative medicine advanced therapy (RMAT) designation. This designation, designed to speed up the development and review of promising therapies, was awarded based on data provided by AskBio, including clinical findings from its Phase Ib open-label, uncontrolled trial, demonstrating AB-1005’s potential to decelerate disease progression and improve motor function in Parkinson’s patients.

Who Are The Major Companies Operating In The Gene Therapy For Parkinson’s Disease Market?

Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

Access The Complete Gene Therapy For Parkinson’s Disease Market Report:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report

Which Regional Market Leads The Gene Therapy For Parkinson’s Disease Market?

North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Gene Therapy For Parkinson’s Disease Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp

Browse Through More Reports Similar to the Global Gene Therapy For Parkinson’s Disease Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Anti Parkinson Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Gene Therapy For Parkinson’s Disease Market Be By 2030 Compared To Its 2026 Market Size?

The gene therapy for parkinson’s disease market size has seen rapid expansion over recent years. It is projected to grow from $0.64 billion in 2025 to $0.81 billion in 2026, achieving a compound annual growth rate (CAGR) of 26.3%. This historical growth can be attributed to advancements in viral vector engineering, a deeper understanding of parkinson’s disease pathology, increased neuroscience research funding, the availability of improved delivery technologies, and successful early clinical trials.

The market size for gene therapy designed to treat Parkinson’s disease is anticipated to experience substantial expansion in the coming years. It is projected to achieve a value of $2.05 billion by 2030, progressing at a compound annual growth rate (CAGR) of 26.0%. This growth during the forecast period can be attributed to factors such as increasing investments in therapies for neurodegenerative diseases, a growing adoption of personalized gene therapy techniques, the broadening of late-stage clinical pipelines, a rising demand for treatments that modify disease progression, and advancements in minimally invasive delivery methods. Key trends during this period are expected to include the increasing development of viral vector-based therapies, a heightened focus on approaches for dopamine restoration, expanded utilization of neurotrophic factor gene delivery, the proliferation of precision intracerebral delivery techniques, and an enhanced emphasis on achieving long-term therapeutic efficacy.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp

What Primary Drivers Are Shaping The Gene Therapy For Parkinson’s Disease Market?

The expanding enthusiasm for personalized medicine is projected to stimulate the expansion of the gene therapy for Parkinson’s disease market in the future. Personalized medicine is defined as a medical methodology that customizes treatment and prevention plans based on an individual’s genetic makeup, lifestyle, and environmental factors. The appeal of personalized medicine is increasing, driven by a rising need for targeted treatments that enhance therapeutic efficacy while reducing negative side effects. Within personalized medicine, gene therapy for Parkinson’s disease utilizes the delivery of customized genetic alterations to reinstate dopamine function and target disease mechanisms specific to individual patients. For example, in February 2024, the US-based non-profit organization, the Personalized Medicine Coalition, indicated that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases, a significant leap from the 6 approvals observed in 2022. Consequently, the rising focus on personalized medicine is propelling the development of the gene therapy for Parkinson’s disease market.

How Is The Gene Therapy For Parkinson’s Disease Market Organized By Segment Classification?

The gene therapy for parkinson’s disease market covered in this report is segmented –

1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy

2) By Vector Type: Viral Vectors, Non-Viral Vectors

3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes

4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods

5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors

2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy

What Trends Are Shaping The Future Of The Gene Therapy For Parkinson’s Disease Market?

Leading companies are actively involved in the gene therapy for Parkinson’s disease market, with efforts concentrated on developing more precise treatments, such as regenerative medicine advanced therapy, to improve neuronal survival, restore dopamine function, and offer long-lasting disease-modifying benefits for patients afflicted with Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) refers to a specific United States Food and Drug Administration (FDA) designation granted to various regenerative medicine products, including cell therapies, gene therapies, and tissue-engineered products, which are designed to treat, modify, reverse, or cure serious or life-threatening ailments. For instance, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy company, introduced AB-1005, an investigational AAV2-GDNF gene therapy that was awarded FDA regenerative medicine advanced therapy (RMAT) designation. This designation, intended to accelerate the development and review of promising therapies, was given based on data provided by AskBio, which included clinical evidence from its Phase Ib open-label, uncontrolled trial, demonstrating AB-1005’s capacity to slow the progression of the disease and enhance motor function in Parkinson’s patients.

Who Are The Industry Participants Involved In The Gene Therapy For Parkinson’s Disease Market?

Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

Get The Full Gene Therapy For Parkinson’s Disease Market Report:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report

Which Region Holds The Highest Market Share In The Gene Therapy For Parkinson’s Disease Market?

North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gene Therapy For Parkinson’s Disease Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report

Browse Through More Reports Similar to the Global Gene Therapy For Parkinson’s Disease Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Anti Parkinson Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Gene Therapy For Parkinson’s Disease Market From 2026 To 2030?

The gene therapy for parkinson’s disease market size has experienced rapid expansion over recent years. This market is projected to expand from $0.64 billion in 2025 to reach $0.81 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 26.3%. Historically, this growth has been driven by several factors, including developments in viral vector engineering, a deeper comprehension of Parkinson’s disease pathology, increased financial support for neuroscience research, the introduction of enhanced delivery technologies, and promising outcomes from initial clinical trials.

The gene therapy for Parkinson’s disease market size is projected for substantial expansion in the coming years. It is set to reach $2.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.0%. This anticipated growth stems from escalating investments in therapies for neurodegenerative conditions, increased adoption of personalized gene therapy methods, the expansion of clinical pipelines in their late stages, a rising need for disease-modifying treatments, and advancements in minimally invasive delivery technologies. Prominent trends throughout this period involve the accelerated development of viral vector-based therapies, a sharpened focus on strategies to restore dopamine, wider application of neurotrophic factor gene delivery, the broadening of precision intracerebral delivery techniques, and a greater emphasis on sustained therapeutic efficacy.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp

What Major Drivers Are Influencing Demand In The Gene Therapy For Parkinson’s Disease Market?

The increasing focus on personalized medicine is anticipated to drive the expansion of the gene therapy for Parkinson’s disease market in the future. Personalized medicine is defined as a medical strategy that customizes treatment and prevention plans based on an individual’s unique genetic profile, lifestyle choices, and environmental factors. The appeal of personalized medicine is increasing, driven by a rising need for focused treatments that enhance efficacy and reduce undesirable side effects. In the context of personalized medicine, gene therapy for Parkinson’s disease is utilized to provide customized genetic alterations aimed at restoring dopamine function and targeting specific disease mechanisms unique to each patient. For example, the Personalized Medicine Coalition, a US-based non-profit, stated in February 2024 that the US Food and Drug Administration (FDA) approved 16 novel personalized treatments for patients with rare diseases in 2023, which represents a significant rise from the 6 approvals recorded in 2022. Consequently, the expanding interest in personalized medicine is fueling the growth of the gene therapy for Parkinson’s disease market.

Which Segments Are Included In The Analysis Of The Gene Therapy For Parkinson’s Disease Market?

The gene therapy for parkinson’s disease market covered in this report is segmented –

1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy

2) By Vector Type: Viral Vectors, Non-Viral Vectors

3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes

4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods

5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors

2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy

Which Trends Are Impacting The Growth Of The Gene Therapy For Parkinson’s Disease Market?

Leading companies in the gene therapy for Parkinson’s disease market are concentrating on creating advanced treatments like regenerative medicine advanced therapy. Their aim is to improve neuronal survival, bring back dopamine function, and offer enduring disease-modifying advantages for individuals with Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) denotes a particular designation from the United States Food and Drug Administration (FDA). This designation is given to regenerative medicine items, including cell therapies, gene therapies, and tissue-engineered products, which are designed to address, alter, reverse, or cure critical or life-threatening conditions. For example, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy firm, launched AB-1005. This investigational AAV2-GDNF gene therapy obtained the FDA regenerative medicine advanced therapy (RMAT) designation. This designation, aimed at accelerating the development and assessment of promising treatments, was awarded following data submission by AskBio. This included clinical evidence from its Phase Ib open-label, uncontrolled trial, which showcased AB-1005’s capability to decelerate disease progression and enhance motor function in Parkinson’s patients.

Which Key Industry Participants Are Active In The Gene Therapy For Parkinson’s Disease Market?

Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

Read the full gene therapy for parkinson’s disease market report here:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Gene Therapy For Parkinson’s Disease Market?

North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gene Therapy For Parkinson’s Disease Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28231&type=smp

Browse Through More Reports Similar to the Global Gene Therapy For Parkinson’s Disease Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Anti Parkinson Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the gene therapy for parkinson’s disease market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Gene Therapy For Parkinson’s Disease Market?

The gene therapy for parkinson’s disease market size has seen significant growth in recent years. This market is anticipated to increase from $0.64 billion in 2025 to $0.81 billion in 2026, achieving a compound annual growth rate (CAGR) of 26.3%. The expansion observed historically stems from progress in viral vector engineering, a greater comprehension of parkinson’s disease pathology, increased funding for neuroscience research, the introduction of enhanced delivery technologies, and successful early clinical trials.

The gene therapy for parkinson’s disease market is projected to undergo significant expansion in the foreseeable future. It is forecasted to achieve a value of $2.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.0%. This anticipated growth is linked to factors such as increased financial commitments to neurodegenerative disease treatments, the escalating adoption of tailored gene therapy strategies, the advancement of clinical pipelines into late stages, a growing need for treatments that modify the disease’s progression, and enhancements in minimally invasive delivery techniques. Prominent developments expected during this period involve the increasing creation of viral vector-based therapies, a heightened focus on dopamine restoration methods, the expanding application of neurotrophic factor gene delivery, the proliferation of precision intracerebral delivery techniques, and a stronger emphasis on ensuring long-term therapeutic efficacy.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp

What Drivers Are Supporting Technological Adoption In The Gene Therapy For Parkinson’s Disease Market?

The expanding focus on personalized medicine is anticipated to fuel the expansion of the gene therapy for Parkinson’s disease market in the future. Personalized medicine defines a healthcare method designed to customize treatment and prevention plans according to an individual’s genetic profile, way of life, and surroundings. The heightened appeal of personalized medicine stems from an increasing need for specific treatments that boost efficacy and reduce negative side effects. Within personalized medicine, gene therapy for Parkinson’s disease is utilized to provide custom genetic alterations aimed at restoring dopamine function and addressing unique disease pathways in individual patients. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, announced that the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, which represents a significant rise from the 6 approvals in 2022. Consequently, the rising attention to personalized medicine is propelling the growth of the gene therapy for Parkinson’s disease market.

What Segment Types Are Examined In The Gene Therapy For Parkinson’s Disease Market?

The gene therapy for parkinson’s disease market covered in this report is segmented –

1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy

2) By Vector Type: Viral Vectors, Non-Viral Vectors

3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes

4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods

5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors

2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy

What Trends Are Reshaping The Dynamics Of The Gene Therapy For Parkinson’s Disease Market?

Leading companies are active in the gene therapy for Parkinson’s disease market, concentrating on developing more precise treatments, such as regenerative medicine advanced therapy, to enhance neuronal survival, restore dopamine function, and provide long-lasting disease-modifying benefits for patients with Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) refers to a particular United States Food and Drug Administration (FDA) designation granted to regenerative medicine products, including cell therapies, gene therapies, and tissue-engineered products, that are intended to treat, modify, reverse, or cure serious or life-threatening diseases. For instance, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy company, introduced AB-1005, an investigational AAV2-GDNF gene therapy that received FDA regenerative medicine advanced therapy (RMAT) designation. This designation, which aims to expedite the development and review of promising therapies, was granted based on data submitted by AskBio, including clinical evidence from its Phase Ib open-label, uncontrolled trial, demonstrating AB-1005’s potential to slow disease progression and improve motor function in Parkinson’s patients.

Who Are The Major Companies Operating In The Gene Therapy For Parkinson’s Disease Market?

Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Gene Therapy For Parkinson’s Disease Market?

North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gene Therapy For Parkinson’s Disease Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28231&type=smp

Browse Through More Reports Similar to the Global Gene Therapy For Parkinson’s Disease Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Anti Parkinson Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Gene Therapy For Parkinson’s Disease Industry By The Forecast Year 2029?

The gene therapy for parkinson’s disease market has seen substantial growth over the past few years. This market is projected to expand from $0.51 billion in 2024 to $0.64 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 26.5%. Historically, this growth has been driven by factors such as the increasing incidence of Parkinson’s disease, a heightened need for personalized treatment options, greater understanding and acceptance of gene therapy, the enlargement of clinical trial infrastructure, and augmented investment in research for neurodegenerative conditions.

The gene therapy for parkinson’s disease market is poised for significant expansion in the coming years. This market is forecast to expand to $1.62 billion by 2029, achieving a compound annual growth rate (CAGR) of 26.1%. Factors driving this growth throughout the forecast period include the increasing uptake of viral vector-based therapies, heightened investments in gene therapy startups, enhanced government assistance for rare disease treatments, the expansion of research partnerships, and the advancing healthcare infrastructure in emerging markets. Key trends during the forecast period involve technological progress in viral delivery systems, novel developments in neurotrophic factor therapies, the creation of targeted gene-editing constructs, increased research and development investments, and evolving precision medicine approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp

Which Drivers Are Impacting The Gene Therapy For Parkinson’s Disease Market?

The expanding focus on personalized medicine is anticipated to fuel the expansion of the gene therapy for Parkinson’s disease market in the future. Personalized medicine defines a medical methodology that customizes treatment and prevention tactics according to an individual’s unique genetic profile, way of life, and surroundings. The demand for personalized medicine is increasing, driven by the need for specific therapies that enhance treatment efficacy while reducing negative side effects. Within personalized medicine, gene therapy for Parkinson’s disease is utilized to provide customized genetic alterations that restore dopamine function and target disease mechanisms unique to each patient. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, announced that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases, which represents a significant rise from the 6 approvals observed in 2022. Consequently, the heightened interest in personalized medicine is propelling the development of the gene therapy for Parkinson’s disease market.

What Are The Emerging Segments Gaining Attention In The Gene Therapy For Parkinson’s Disease Market?

The gene therapy for parkinson’s disease market covered in this report is segmented as

1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy

2) By Vector Type: Viral Vectors, Non-Viral Vectors

3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes

4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods

5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegment:

1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors

2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy

How Are Trends Influencing The Gene Therapy For Parkinson’s Disease Market?

Within the gene therapy for Parkinson’s disease market, leading companies are concentrating on creating more exact treatments, such as regenerative medicine advanced therapy. The aim is to improve neuronal survival, bring back dopamine function, and offer sustained disease-modifying advantages for individuals suffering from Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) represents a specific United States Food and Drug Administration (FDA) designation awarded to regenerative medicine products, including cell therapies, gene therapies, and tissue-engineered products, that aim to treat, modify, reverse, or cure serious or life-threatening conditions. For example, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy firm, launched AB-1005, an investigational AAV2-GDNF gene therapy that obtained FDA regenerative medicine advanced therapy (RMAT) designation. This designation, designed to accelerate the development and review process for promising therapies, was awarded based on data provided by AskBio, including clinical findings from its Phase Ib open-label, uncontrolled trial, showing AB-1005’s capacity to slow the progression of the disease and enhance motor function in Parkinson’s patients.

Who Are The Major Companies Operating In The Gene Therapy For Parkinson’s Disease Market?

Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gene-therapy-for-parkinsons-disease-global-market-report

Which Regional Markets Are Contributing Most To The Gene Therapy For Parkinson’s Disease Industry Expansion?

North America was the largest region in the gene therapy for parkinson’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene therapy for parkinson’s disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Gene Therapy For Parkinson’s Disease Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28231&type=smp

Browse Through More Reports Similar to the Global Gene Therapy For Parkinson’s Disease Market 2025, By The Business Research Company

Genes Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Anti Parkinson Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Nucleic Acid Based Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model